Platelet mass has prognostic value in patients with myelodysplastic syndromes

Kristian M Bowles, Brian A Warner, Trevor P Baglin

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)


Platelet mass (mean platelet volume x platelet count) can be derived from data obtained from the routine full blood count and separates patients with myelodysplastic syndromes (MDS) at diagnosis into three distinct prognostic groups: low platelet mass group - median survival 5 months and 5-year survival 0%; intermediate platelet mass group - median survival 30 months and 5-year survival 34%; high platelet mass group median survival - not reached at 82 months follow-up with a 5-year survival of 82%. These data provide a simple rapid prognostic index at the time of diagnosis in MDS.
Original languageEnglish
Pages (from-to)198-200
Number of pages3
JournalBritish Journal of Haematology
Issue number2
Publication statusPublished - Oct 2006


  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Platelets
  • Cell Size
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes
  • Platelet Count
  • Prognosis
  • Survival Analysis

Cite this